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DObjectives: Patient selection is crucial to achieve good outcomes and to avoid futile procedures in patients
undergoing transcatheter aortic valve replacement. The aim of this multicenter retrospective studywas to identify in-
dependent predictors of 1-yearmortality in patients surviving after transapical transcatheter aortic valve replacement.
Methods: We analyzed data from the Italian registry of transapical transcatheter aortic valve replacement that
includes patients undergoing operation in 21 centers from 2007 to 2012. Futility was defined as mortality within
1 year after transapical transcatheter aortic valve replacement in patients surviving at 30 days. Thirty-day
survivors were divided in 2 groups: futility (group F) and nonfutility (group NF). Cox proportional hazard
regression analysis was performed to identify independent predictors of futility.
Results: We analyzed data from 645 patients with survival of 30 days or more after transapical transcatheter
aortic valve replacement. Groups F and NF included 60 patients (10.8%) and 585 patients (89.2%), respectively.
Patients in group F were more likely to have insulin-dependent diabetes (15% vs 7.2%, P¼ .03), creatinine 2.0
mg/dL or greater or dialysis (18.3% vs 8.2%, P ¼ .01), logistic European System for Cardiac Operative Risk
Evaluation greater than 20% (66.7% vs 50.3%, P ¼ .02), preoperative rhythm disorders (40% vs 25.3%,
P ¼ .03), critical preoperative state (8.3% vs 1.8%, P ¼ .002), and left ventricular ejection fraction less than
30% (15% vs 2.9%, P<.001). The multivariate analysis identified the following as independent predictors
of futility: insulin-dependent diabetes (odds ratio, 3.1; P ¼ .003), creatinine 2.0 mg/dL or greater or dialysis
(odds ratio, 2.52; P ¼ .012), preoperative rhythm disorders (odds ratio, 1.88; P ¼ .04), and left ventricular
ejection fraction less than 30% (odds ratio, 4.34; P ¼ .001).
Conclusions:According toour data, amongpatients undergoing transapical transcatheter aortic valve replacement,
thosewith insulin-dependent diabetes, advanced chronic kidney disease, rhythm disorders, and low left ventricular
ejection fraction have a higher risk to undergo futile procedures. (J Thorac Cardiovasc Surg 2014;148:973-80)Transcatheter aortic valve replacement (TAVR) is a
well-established technique for inoperable or high-risk
patients with severe symptomatic aortic valve stenosis
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Dcomorbidities.6 In fact, TAVR is expensive in terms of cost
of devices and of human, structural, and logistic resources.
It has been demonstrated that patient selection is crucial to
achieve good postoperative outcomes after TAVR.7
Cost-effectiveness studies on TAVR focus their attention
on the gain of quality-adjusted life years (QALYs); conse-
quently poor postoperative survival, even if it occurs after
an uneventful operation, will result in an ineffective proce-
dure under both the clinical and the financial point of views.
Therefore, the selection of very elderly patients or patients
with extremely high preoperative risk profiles may lead to
technically successful operations but also to short postoper-
ative survival, thus making futile such an expensive and
complex procedure. In particular, the cost-effectiveness of
transapical TAVR (TA-TAVR) is less evident than transfe-
moral TAVR.8,9 Thus, particular attention should be given
during the evaluation of patients for TA-TAVR. Several
studies have reported on the predictors of 30-day and
1-year mortality in patients undergoing TAVR1,10-14;
however, there are a lack of data on the clinical features
of patients who survive the procedure and are successfully
discharged from the hospital but then die early during
follow-up. The identification of predictors of early mortal-
ity in patients surviving TA-TAVR may help to better select
TAVR candidates to optimize results and use of resources
and may also help to identify the patients with a high risk
of early death after a successful operation to improve
preoperative counseling with patients and their families.
For this reason, in the present retrospective multicenter
study, we aimed at identifying the independent predictors
of 1-year mortality in patients surviving after TA-TAVR.
METHODS
Patient-informed consent for treatment and data collection and analysis
for scientific purposes was always collected; the ethics committees approved
the data collection of patients undergoing TAVR. Indications for TA-TAVR
were severe symptomatic aortic valve stenosis (defined as aortic valve area
<0.8 cm2 and mean transaortic gradient>40 mm Hg) together with 1 or974 The Journal of Thoracic and Cardiovascular Surgmore of the following conditions: porcelain aorta; high surgical risk (logistic
European System for Cardiac Operative Risk Evaluation [euroSCORE] I
>20% or Society of Thoracic Surgeons predicted risk of mortality
>10%); or serious comorbidities, including chronic kidney failure, chronic
obstructive pulmonary disease, previous total chest irradiation, hostile chest,
or severe liver disease. The absolute contraindications for TA-TAVR were
left ventricular aneurysm with or without thrombotic stratification and an
extremely poor left ventricular ejection fraction (LVEF) (<15%). All cases
were evaluatedbyamultidisciplinaryTAVRteam that included a cardiac sur-
geon and an interventional cardiologist. Most centers that participate in the
Italian Registry of Trans-Apical Aortic Valve Implantation (I-TA) registry
adopt a ‘‘transfemoral first’’ policy. However, few centers follow a different
strategy; thus, some patients received a TA-TAVR even without severe
peripheral vascular disease. The procedures were performed under general
anesthesia with orotracheal intubation in a hybrid operating room or a
catheterization laboratory, according to the logistics of each center. In this
study, we used the Sapien and, since mid-2010, the Sapien XT transcatheter
valves (Edwards Lifesciences, Irvine, Calif). All details about the I-TA
registry, including the cardiac surgery sites and investigators, TA-TAVR
technique, device characteristics, sizing, postoperative medications, data
collection, and analysis, have been described.1,10 Futility was defined as
1-year mortality in patients who did not experience 30-day all-cause
mortality according to the Valve Academic Research Consortium
definitions.15,16 Patients surviving 30 days after TA-TAVRwere then divided
into 2 groups: the futility (group F), including patients surviving less than
12 months, and the nonfutility (group NF), including patients surviving
12 months or more. Preoperative risk factors were defined according to the
euroSCORE I classification.17 Preoperative rhythm disorders were defined
as permanent atrial fibrillation or the presence of a definitive pacemaker.
Statistical Analysis
For continuous variables, data are reported as mean with standard
deviation or median with interquartile range, according to the nature of
variables distribution. For categoric variables, data are reported as
frequency (percentage). Comparison between groups for continuous
variables was made using the t test or the Wilcoxon Mann–Whitney test
as appropriate; comparison between groups for categoric variables was
made using the chi-square or Fisher exact test as appropriate. Cox propor-
tional hazard regression analysis was performed to identify independent
predictors of futility that are reported as hazard ratio (HR), 95% confidence
interval, and P value. All statistical tests were 2-sided. Statistical analyses
were conducted using SAS version 9.2 (SAS Institute, Inc, Cary, NC).
RESULTS
From April 2008 to June 2012, a total of 774 patients had
been enrolled in the I-TA registry. For this study, we
excluded from the analysis 77 patients (9.9%) who
experienced 30-day mortality and 52 patients (6.7%) with
a follow-up less than 12 months. We analyzed data
from 645 patients with survival 30 days or more after
TA-TAVR and at least 1-year follow-up. Group F included
60 patients (10.8%), and group NF included 585 patients
(89.2%). Preoperative clinical variables are listed in
Table 1. Age (F: 80.1  9.5 years vs NF: 81.2  6.4 years,
P¼ .4) and sex (female sex, F: 50% vs NF: 58.8%,P¼ .18)
were not different between groups. Patients in group F were
more likely to have diabetes (41.7% vs 25.8%, P ¼ .009)
and insulin-dependent diabetes (15% vs 7.2%, P ¼ .03);
to have chronic kidney disease and in particular to have
creatinine 2.0 mg/dL or greater or dialysis (18.3% vs
8.2%, P ¼ .01) and worse glomerular filtration rateery c September 2014
TABLE 1. Preoperative clinical variables
Variable All patients (n ¼ 645) Group F (n ¼ 60) Group NF (n ¼ 585) P value
Age (y,%) 81.2  6.4 80.1  9.5 81.2  6.4 .41
Sex (female,%) 374 (58) 30 (50) 344 (58.8) .18
Arterial hypertension (%) 554 (85.9) 50 (83.3) 535 (91.5) .55
Diabetes (%) 176 (27.3) 25 (41.7) 151 (25.8) .009
Insulin treatment (%) 51 (7.9) 9 (15) 42 (7.2) .03
NYHA class
I 8 (1.2) 0 (0) 8 (1.4) .14
II 101 (15.7) 5 (8.3) 98 (16.8)
III 341 (52.9) 39 (65) 301 (51.5)
IV 195 (30.2) 16 (26.7) 178 (30.4)
PVD (%) 308 (47.8) 30 (50) 278 (47.5) .71
COPD (%) 208 (32.2) 21 (35) 187 (32) .63
Neurologic dysfunction (%) 52 (8.1) 5 (8.3) 47 (8) .94
CKD (%) 59 (9.1) 1 (18.3) 48 (8.2) .001
GFR (mL/min) 49.3  26.3 40.4  16.9 49.3  26.2 .001
Preoperative serum creatinine (mg/dL) 1.2  0.6 1.4  0.7 1.2  0.6 .007
Liver cirrhosis (%) 4 (0.6) 2 (3) 2 (0.3) .06
Preoperative rhythm disorders .032
AF (%) 139 (21.6) 18 (30) 121 (20.7)
PM (%) 33 (5.1) 6 (10) 27 (4.6)
Critical preoperative state (%) 16 (2.5) 5 (8.3) 11 (1.9) .002
CAD (%) 317 (58) 29 (48.3) 288 (49.2) .74
LVEF (%) 53.7  12 49  15.4 53.7  12 .02
LVEF<30% (%) 26 (4) 9 (15) 17 (2.9) <.0001
PAPs (mm Hg) 42.4  13 45.1  11.6 42.4  12.9 .20
Severe MR (%) 112 (17.4) 14 (23.3) 98 (16.8) .06
Porcelain aorta (%) 88 (13.6) 9 (15) 79 (13.5) .75
Previous cardiac surgery (%) 141 (21.9) 14 (23.3) 127 (21.7) .77
Logistic euroSCORE (%) 24.2  15.3 30  17.8 24.2  15.3 .008
STS PROM (%) 10  7.9 11.8  5.6 10  7.8 .28
Peak aortic gradient (mm Hg) 81.7  21.9 77.5  25.7 81.7  21.9 .17
Mean aortic gradient (mm Hg) 50.8  14.9 47.4  16.6 50.8  14.9 .01
AVA (cm2) 0.7  0.2 0.68  0.16 0.74  0.17 .02
AVAi (cm2/m2) 0.4  0.1 0.41  0.09 0.44  0.1 .05
Aortic annulus diameter (mm) 22.1  2 21.9  2.1 22.1  2 .54
AF, Atrial fibrillation; AVA, aortic valve area; AVAi, indexed aortic valve area;CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary
disease; euroSCORE, European System for Cardiac Operative Risk Evaluation; F, futility; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; MR, mitral
regurgitation; NF, nonfutility; NYHA, New York Heart Association; PAPs, systolic pulmonary artery pressure; PM, pacemaker; PROM, predicted risk of mortality; PVD, periph-
eral vascular disease; STS, Society of Thoracic Surgeons.
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D(40.4 16.9 mL/min vs 49.3 26.3 mL/min, P¼ .001); to
have lower LVEF (49%  15.4%, P ¼ .02) and preopera-
tive rhythm disorders (40% vs 25.3%,P¼ .03); and to be in
a critical preoperative state (8.3% vs 1.8%, P ¼ .003). Lo-
gistic euroSCORE values were higher in group F (30% 
17.8% vs 24.2%  15.3%, P ¼ .008), although we did
not observe differences in the Society of Thoracic Surgeons
prediction of mortality (11.8%  5.6% vs 10%  7.9%,
P ¼ .28). Furthermore, patients in group F apparently had
a more severe degree of aortic valve stenosis as confirmed
by measurement of aortic valve area (0.68  0.16 cm2 vs
0.74  0.17 cm2, P ¼ .02). Perioperative and postoperative
outcomes are shown in Table 2. Perioperative data show that
length of stay in the intensive care unit (median value, 24
hours in both groups, P ¼ .82) and the hospital (medianThe Journal of Thoracic and Cavalue, F: 10 days, NF: 8 days, P¼ .72) was not different be-
tween groups. The incidence of moderate and severe aortic
regurgitation at discharge was significantly higher in group
F (13.3% vs 5.6%,P¼ .02). The Valve Academic Research
Consortium (VARC) combined safety end point at 30 days,
which includes major stroke, life-threatening (or disabling)
bleeding, acute kidney injury stage 3 (including renal
replacement therapy), periprocedural myocardial infarc-
tion, major vascular complication, and repeat procedure
for valve-related dysfunction (surgical or interventional
therapy), was not different between groups because it
occurred in 18.3% and 10.3% of patients in groups F and
NF, respectively (P ¼ .06). On the other hand, VARC-2
early safety at 30 days combined end point, which includes
all strokes (disabling and nondisabling), life-threateningrdiovascular Surgery c Volume 148, Number 3 975
TABLE 2. Perioperative and postoperative outcomes
All patients (n ¼ 645) Group F (n ¼ 60) Group NF (n ¼ 585) P value
ICU LOS (h) (median and range) 24 (23-48) 24 (22-48) 24 (23-48) .82
Hospital LOS (d) (median and range) 8 (7-12) 10 (7-14) 8 (7-12) .72
Aortic PG (mm Hg) 21  9.1 20.5  11.6 21  9 .80
Aortic MG (mm Hg) 10.2  4.1 9  3.8 10.2  4 .05
LVEF (%) 54.3  9.8 52  11.8 54.3  9.8 .10
Intraoperative complications
Prosthesis embolization 3 (0.5) 0 3 (0.5) 1.00
Need for CPB 8 (1.2) 1 (1.7) 7 (1.2) .54
Need for sternotomy 3 (0.5) 0 3 (0.5) 1.00
Access site complications 7 (1.1) 1 (1.7) 6 (1.0) .50
Need for CPR 11 (1.7) 2 (3.3) 9 (1.5) .27
Coronary occlusion 2 (0.3) 0 2 (0.3) 1.00
Aortic dissection 1 (0.2) 0 1 (0.2) 1.00
Need for valve-in-valve 3 (0.5) 0 3 (0.5) 1.00
Postoperative AMI 7 (1.1) 1 (1.7) 6 (1.0) .99
Postoperative stroke (all) 4 (0.6) 2 (3.3) 2 (0.4) .09
Life-threatening bleeding 44 (6.8) 8 (13.3) 36 (6.1) .04
AKIN grade 2-3 49 (12.7) 6 (16.0) 43 (12.4) .41
Postoperative PPM implantation 38 (5.9) 4 (6.7) 34 (5.8) .77
Moderate-severe AR at discharge (%) 41 (6.4) 8 (13.3) 33 (5.6) .02
VARC-1 combined safety at 30 d (%) 71 (11) 11 (18.3) 60 (10.3) .06
VARC-2 early safety at 30 d (%) 91 (14.1) 14 (23.3) 77 (13.2) .03
AKIN, Acute Kidney Injury Network; AMI, acute myocardial infarction; AR, aortic regurgitation; CPB, cardiopulmonary bypass; CPR, cardiopulmonary resuscitation; F, futility;
ICU, intensive care unit; LOS, length of stay; LVEF, left ventricle ejection fraction;MG, mean gradient; NF, nonfutility; PG, peak gradient; PPM, permanent pacemaker implan-
tation; VARC, Valve Academic Research Consortium.
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Dbleeding, acute kidney injury stage 2 or 3 (including renal
replacement therapy), coronary artery obstruction requiring
intervention, major vascular complication, and valve-
related dysfunction requiring repeat procedure was signifi-
cantly higher in group F (23.3% vs 13.2%, P ¼ .03).
VARC-1 and VARC-2 safety end points at 30 days also
include all-cause mortality, but this variable was not consid-
ered in the analysis because these patients were excluded
from this study. Causes of cardiovascular and noncardiovas-
cular mortality within 1 year after the operation are listed in
Table 3.18 Among cardiovascular and noncardiovascular
mortality, cardiac failure (13 patients, 21.7%) and respira-
tory failure (11 patients, 18.3%) are the 2 most common
causes of death, respectively. The mean time from
procedure to death of patients belonging to group F was
181  117 days. To assess how preoperative variables
affected postoperative outcomes but also to fully
understand the impact of perioperative events on futility,
in particular moderate-severe AR and safety end points,
we performed the multivariate analysis in 4 different
scenarios: on the entire cohort, with the exclusion of
patients with AR 2þ or greater, with the exclusion of
patients with an early safety end point (according to
VARC-2), and with the exclusion of patients with AR 2þ
or greater and patients with an early safety end point.
Table 4 shows the results of the multivariate analysis. In
particular, the multivariate analysis performed on the entire
cohort identified the following independent predictors of976 The Journal of Thoracic and Cardiovascular Surgfutility: insulin-dependent diabetes (odds ratio [OR], 3.1;
P ¼ .003), creatinine 2.0 mg/dL or greater or dialysis
(OR, 2.52; P ¼ .012), preoperative rhythm disorders (OR,
1.88; P ¼ .04), and LVEF less than 30% (OR, 4.34;
P ¼ .001). If we exclude patients with postoperative AR
2þ or greater from the analysis, insulin-dependent diabetes,
chronic kidney disease, and poor LVEF are still independent
predictors of futility, but rhythm disorders are not signifi-
cant. On the other hand, when patients who experienced
an early safety end point are excluded from the analysis,
insulin-dependent diabetes and poor LVEF are still
independent predictors of futility in association with
preoperative critical state (OR, 3.58; P ¼ .02). Last, when
patients with postoperative AR 2þ or greater and patients
with an early safety end point are excluded from the
multivariate analysis, insulin-dependent diabetes, critical
preoperative state, and poor LVEF are still identified as
independent predictors of futility in patients undergoing
TA-TAVR. Therefore, insulin-dependent diabetes and
poor LVEF are always identified as independent predictors
of futility, whereas critical preoperative state and rhythm
disorders, even if they do not reach the statistical signifi-
cance in all the multivariate analyses, are predictors to note.
DISCUSSION
In this study, we analyzed data from the I-TA registry to
identify preoperative independent predictors of futility in
patients undergoing TA-TAVR. Futility was defined asery c September 2014
TABLE 3. Causes of death
Cardiovascular
mortality* (n ¼ 25)
Noncardiovascular
mortality* (n ¼ 35)
Cardiac failure 13 Lung disease 11
Unknown 4 Infection, sepsis 7
Sudden death/arrhythmias 4 Cancer 5
Stroke 1 Cachexia, cognitive impairment 4
AVSD 1 Acute renal insufficiency 3
Pulmonary embolism 1 Cirrhosis 2
Right myocardial infarction 1 Parkinson’s disease 2
Gastrointestinal bleeding 1
AVSD, Atrioventricular septal defect. *VARC definitions.15,16 See Salizzoni and
colleagues.18
D’Onofrio et al Acquired Cardiovascular Disease1-year mortality in patients surviving 30 days after
TA-TAVR. Themain findings of this analysis are that a futile
procedure is performed in approximately 10% of patients
undergoing TA-TAVR, that the majority of these patients
diewithin 6months after the operation, and that preoperativeTABLE 4. Preoperative risk factors for ‘‘futile’’ procedures at 1 year
HR 95% CI P value
All patients, n ¼ 645
Age 1.000 0.965-1.035 .98
Gender female 0.767 0.459-1.281 .31
IDDM 2.343 1.134-4.041 .02
CKD 1.978 1.012-3.865 .05
CPS 1.970 0.684-5.671 .21
Rhythm disorders 1.713 1.006-2.918 .05
LVEF<30 3.267 1.418-7.531 .01
Postoperative AR 2 excluded, n ¼ 604
Age 0.993 0.960-1.027 .68
Gender female 0.687 0.395-1.195 .18
IDDM 2.619 1.252-5.475 .01
CKD 2.068 1.007-4.246 .05
CPS 2.680 0.888-8.092 .08
Rhythm disorders 1.727 0.971-3.071 .06
LVEF<30 3.105 1.241-7.769 .02
VARC-2 early safety excluded, n ¼ 554
Age 1.032 0.987-1.080 .16
Gender female 0.682 0.377-1.235 .21
IDDM 3.525 1.623-7.654 .002
CKD 1.144 0.438-2.990 .78
CPS 3.581 1.216-10.544 .02
Rhythm disorders 1.686 0.925-3.072 .09
LVEF<30 5.586 2.468-12.639 <.001
Postoperative AR 2 and VARC-2 early safety excluded, n ¼ 520
Age 1.023 0.980-1.068 .30
Gender female 0.713 0.379-1.341 .29
IDDM 4.017 1.823-8.852 <.001
CKD 1.368 0.505-3.704 .54
CPS 4.221 1.386-12.861 .01
Rhythm disorders 1.779 0.938-3.373 .08
LVEF<30 5.174 2.102-12.736 <.001
AR, Aortic regurgitation; CI, confidence interval; CKD, chronic kidney disease; CPS,
Critical Preoperative State (as defined by euroSCORE); HR, hazard ratio; IDDM,
insulin-dependent diabetes mellitus; LVEF, left ventricular ejection fraction; VARC,
Valve Academic Research Consortium.
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Dinsulin-dependent diabetes, kidney function impairment,
rhythm disorders, and poor LVEF may predict futility in
this cohort of patients. Furthermore, critical preoperative
state is another predictor of futility in patients who undergo
an uneventful TA-TAVR operation followed by an unevent-
ful postoperative hospital stay. What is futility in medicine?
An action cannot be considered futile unless its goal is
clearly stated.19 Futility is the lack of effectiveness or suc-
cess in doing something because it does not provide appro-
priate, expected, or desired results. If the goal of TAVR in
very high-risk patients is to treat aortic valve stenosis to
improve a patient’s life expectancy and then the patient
dies earlier than expected, that procedure should be consid-
ered futile. Conversely, if the goal of the operation is to give a
chance of survival to a patient whose bad prognosis is due to
the natural history of the disease, that procedure is not futile
even if the patient dies early. Things change if we only look
at the financial cost-effectiveness aspect. In this case, a futile
heart procedure is an operation that despite its costs in terms
of financial, technical, and human resources does not pro-
long life duration or provide an improvement of patients’
clinical conditions, even if it is successfully carried out. Ac-
cording to the recently published American Heart Associa-
tion/American College of Cardiology guidelines for the
management of patients with valvular heart disease, TAVR
is recommended in patients with a predicted post-TAVR sur-
vival more than 12 months.20 The majority of studies that
analyze cost-effectiveness of TAVR evaluate the number
of QALYs to assess the incremental cost-effectiveness ratio
per QALYs gained. QALY is a parameter that takes into
consideration both survival and quality of life after the oper-
ation.21 QALYs gained after a TAVR operation range from
0.60 to 1.56.22 Consequently, patients with a short postoper-
ative survival have a negative impact under a cost-
effectiveness point of view. Another important aspect is
that in patients deemed inoperable only for anatomic reasons
(eg, porcelain aorta), the cost-effectiveness of TAVR is even
more evident because it is likely that they do not have all the
several associated diseases that are present in patients with
high-risk scores due to multiple comorbidities. In the NF
cohort, the variables that were independently associated
with futility, insulin-dependent diabetes, chronic kidney dis-
ease, preoperative rhythm disorders, and poor LVEF were
present in 7.2%, 8.2%, 25.3%, and 2.9% of patients,
respectively. This means that despite these factors, they
did not undergo a futile procedure, and consequently TA-
TAVR should not be denied in all patients presenting with
these comorbidities. Therefore, a multidisciplinary careful
evaluation of patient’s global clinical state should be made
before denying the procedure. Furthermore, in-depth preop-
erative counseling is mandatory to share the decision with
patients and their families. It is interesting to observe that pa-
tients with a short postoperative survival had a higher rate of
postoperative moderate-severe aortic regurgitation. Theserdiovascular Surgery c Volume 148, Number 3 977
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Dresults confirm the findings of Schewel and colleagues,23
who report an increased mortality in TAVR cases within 6
months if an at least moderate paravalvular leak was
accepted as the final result of the procedure. The impact of
aortic regurgitation on survival after TAVR was first intro-
duced by the 2-year Placement of Aortic Transcatheter
Valve trial report, in which it appeared that the presence of
paravalvular or total aortic regurgitation (mild, moderate,
or severe vs none or trace) after TAVR was associated with
increased late mortality and that the effect of aortic regurgi-
tation on mortality was proportional to the severity of the
regurgitation.24 It is still debated whether even mild insuffi-
ciency might have an impact on survival because in other
studies it was not associated with an increase of late postop-
erative mortality.25 Patients dying within 1 year after TAVR
also had a higher incidence of 30-day safety events, defined
as following VARC-2 recommendations. This confirms the
results of one of our previous studies from the I-TA registry.
In that article, we showed that patients who experienced an
intraoperative complication had a significantly lower 18-
month survival when compared with patients without any
complication.10 However, to avoid a potentially confound-
ing impact of perioperative adverse events on the interpreta-
tion of these results, we performed the multivariate analysis
excluding patients with postoperative moderate-severe AR
and patients with a perioperative adverse event. Insulin-
dependent diabetes is always identified as an independent
predictor of futility; therefore, it should be considered a
strong one. Insulin-dependent diabetes has already been
described as an independent predictor of adverse events after
TAVR, in particular for death andmyocardial infarction, and
it has been claimed to be included in future TAVR-dedicated
risk scores.26 Critical preoperative state (defined as
according to the euroSCORE definitions) becomes a strong
predictor of futility in patients with uneventful surgery and
hospital stay, but it should always be considered as an
important factor because it is present in all the analyses
even if it does not always reach statistical significance.
Study Limitations
A strong limitation of this study is that we do not have
data about frailty and quality of life, which are important
aspects of a patient’s evaluation and may have an impact
on patient survival after surgery. Furthermore, data on
quality of life during follow-up might provide information
about another important aspect of futility, other than death,
that has not been taken into account in this study. We do not
have a central echocardiographic Core-Lab, and adverse
events were assigned by each participating center and not
by an ad hoc committee.
CONCLUSIONS
According to our data, approximately 10% of patients
who survive TA-TAVR die within 1 year after the operation.978 The Journal of Thoracic and Cardiovascular SurgInsulin-dependent diabetes, poor left ventricle ejection
fraction, rhythm disorders, and chronic kidney disease are
independent predictors of futility. Patients in a critical
preoperative state have a higher risk to undergo a futile
procedure even if the operation and subsequent hospital
stay are totally uneventful. All these factors should be
carefully considered when screening TA-TAVR cases to
optimize clinical outcomes and to provide a comprehensive
preoperative counseling to patients and their families.References
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Discussion
Dr Wilson Szeto (Philadelphia, Pa). I congratulate you on a
well-done study. My disclosure is that I am an investigator in the
PARTNER trial at our institution at the University of Pennsylvania.
This presentation is a timely and important topic. We have all
struggled with the question of futility versus utility in these pa-
tients. The so-called eyeball test is what you are referring to; how
do we determine which patients are ‘‘too sick’’ for even TAVR?
I applaud you and agree with you in your multivariate analysis
that we have now learned that factors such as end points in VARC-
2 and mild paravalvular leak may have a late impact on outcome. I
applaud you for an in-depth analysis eliminating those factors
when you examine your multivariate analysis predictors of death.
One of the issues that we have struggled with over the last few
years in terms of determining what is considered futile is this
whole question of an ‘‘eyeball test’’ and noncardiac factors that
are not captured in the Society of Thoracic Surgeons predicted
risk of mortality, such as frailty, dementia, cirrhosis. Do you
have any information to share with us regarding these factors in
your patient cohort, and what impact do you think there would
have been on your analysis?
Dr D’Onofrio.We don’t have data about frailty in this registry.
Frailty is difficult to quantify, especially in patients undergoing
cardiac surgery, because there are no specific scores for them.The Journal of Thoracic and CaThere are so many different scores, and these evaluations are
subjective. I cannot answer this question because I don’t have
data on frailty, but it would be interesting to analyze this aspect.
Regarding cirrhosis, we had only 4 patients in this population
(2 in group F and 2 in group NF), and these numbers are too small
to evaluate the impact of this variable on postoperative outcomes.
We believe that dementia is a contraindication to a transcatheter
aortic valve implantation, because it would not improve quality of
life or patient survival. We don’t usually perform TAVI in patients
with dementia.
Dr Szeto.Another important outcome that we have all looked at
in TAVR is the question of functional recovery and quality of life.
Do you have any data to share with us regarding the 2 groups, the F
andNF groups?Were there any differences in thosemetrics in your
study?
DrD’Onofrio. It is difficult to compare these groups in terms of
functional recovery, because the group ‘‘F’’ has a short follow-up.
By looking at the data, we observed that 40% of patients in group
F, futile patients, died of cardiovascular causes. So I suppose the
functional recovery is worse in these patients. But it is difficult
to compare the 2 groups, because these patients have only 6
months follow-up, and the other patients have 4 to 5 years
follow-up.
It would be interesting to analyze these patients in terms of
quality of life, because this is another important aspect of futility.
Unfortunately, we don’t have data on quality of life. It would be
interesting to analyze futility not only in terms of survival but
also in terms of quality of life. So if somebody in the audience
has these data and would like to share it with us, we could extend
this study and maybe present it next year.
Dr Szeto. From a practical standpoint in terms of how you
evaluate patients in your valve clinic, on the basis of your data,
what would you recommend to the rest of us as we try to better
sort out which patients are futile and which patients we should
treat? What would you recommend at this point? You alluded to
it a bit at the end of your presentation.
Dr D’Onofrio. If we honestly believe that a patient would not
improve quality of life or survival with a TAVI, we have to deny
TAVR to that patient. It is crucial to comprehensively counsel
patients and their families. We don’t think that all patients with
these predictors of futility should be excluded tout court from
this procedure. There are, as I showed in the slides, a lot of patients
who, despite chronic kidney disease and with rhythm disorders
that are predictors of futility, had a good outcome after the
procedure. So it is not a good reason to exclude these patients
only because they have these risk factors. Good counseling and
more attention to their procedure and immediate postoperative
period are recommended.
Dr Harold Lazar (Boston, Mass). What type of patients would
you say no to on the basis of your study? What type of patients
would you not offer this technique to?
Dr D’Onofrio. It is impossible to identify exactly what kind of
patients we should say no to. We have to evaluate many things,
such as risk factors and general clinical conditions. The ‘‘eyeball
test’’ is important, especially now that we have some good
experience with these patients. Taking into account all these
factors, we should be able to understand which patients are more
likely to have a poor postoperative outcome.rdiovascular Surgery c Volume 148, Number 3 979
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DDr Lazar. So a 75-year-old patient who is intubated, with
congestive heart failure, inotropes, and worsening kidney function,
would you operate on that patient?
Dr D’Onofrio. If the patient is in an acute phase of disease and
the main cause of the condition is aortic valve disease, I would
operate on this patient. I would not operate on a 92-year-old patient
who has chronic kidney disease, poor mobility, and all the other
well-known associated conditions; to me, this makes no sense.
But if, like you said, a 75-year-old patient has acute heart failure,
I would do it, and actually we did it with good results.
Dr A. Pieter Kappetein (Rotterdam, The Netherlands). The ti-
tle of your presentation is great, and listening to your presentation I
thought, ‘‘He is finally going to tell mewhich patients not to treat.’’
But what you tell us is that diabetes, LVEF, high pulmonary
pressure, kidney disease, and conduction disturbances are not
good. So which of those predictive factors were not surprising
and which were new to you?
Dr D’Onofrio. That is a good point. I would have expected
functional class to be an independent predictor of a bad outcome,
and I would have also expected euroSCORE to be a predictor of a
bad outcome. In our previous articles, euroSCORE and functional
class were identified as risk factors for mortality, so I would have
expected that these factors would have been significant in these
patients also.
Dr Kappetein. This is important, because you can teach us
which variables we should not take into account, for example,
euroSCORE. Is that what you mean?
Dr D’Onofrio. Correct.
Dr Kappetein. This means that we should not take into account
the euroSCORE. Is that what you mean?980 The Journal of Thoracic and Cardiovascular SurgDr D’Onofrio. It seems that just some of the variables that are
included in the euroSCORE should be taken into account, but not
the euroSCORE itself.
Dr Kappetein. Why do you think the euroSCORE is not
predictive then? What is the reason for that?
Dr D’Onofrio. Probably because it takes into account a lot of
variables that don’t have an impact on these particular patients,
and it is not tailored specifically for these high-risk patients with
aortic disease.
Dr Kappetein. So don’t use the euroSCORE in these types of
patients?
Dr D’Onofrio. Well, use it, but rather look at each single
variable included in the euroSCORE. Furthermore, look at the
patient in all aspects.
Dr Lazar. One final quick question. You have been putting
these in, or the registry has documented these, since 2008?
Dr D’Onofrio. Yes.
Dr Lazar. Can you give us some idea what the freedom from
structural deterioration of these valves are and what percent have
had to be replaced?
Dr D’Onofrio.We just updated this registry, and now we have
approximately 1000 patients. We have approximately 5 years
follow-up with a mean follow-up of approximately 2.5 years,
and we haven’t observed any structural valve deterioration so
far. However, the duration of follow-up is still too short.
Dr Lazar. Paravalvular leaks?
Dr D’Onofrio. Paravalvular leaks are approximately 40%,
including mild, moderate, and severe. In particular, moderate
and severe leaks occurred in approximately 8% of patients, and
they have a significant impact on survival in our registry.ery c September 2014
